The world’s largest generic drug manufacturer Teva is presenting new financial targets in connection with its research and development day. The company is targeting revenue from innovative medicines of USD 6–7 billion in 2030.
Teva expects annual growth in total revenue of around 5 percent during the 2026–2030 period. The gross margin for innovative medicines is expected to exceed 75 percent and free cash flow to exceed USD 3.5 billion in 2030.
The company also sees a path to net debt equivalent to 2.0 times adjusted EBITDA at the end of 2027.
Since the growth strategy was launched in 2023, sales of innovative medicines have more than doubled. Teva estimates that medicines in development have combined potential peak sales of more than USD 10 billion.
The company sees an opportunity to launch one new innovative medicine annually through 2030.
